Compare UG & VNRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UG | VNRX |
|---|---|---|
| Founded | 1942 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Package Goods/Cosmetics | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 27.7M | 31.9M |
| IPO Year | 1995 | 2012 |
| Metric | UG | VNRX |
|---|---|---|
| Price | $6.50 | $0.20 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $2.50 |
| AVG Volume (30 Days) | 11.0K | ★ 1.9M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 7.70% | N/A |
| EPS Growth | N/A | ★ 38.00 |
| EPS | ★ 0.20 | N/A |
| Revenue | ★ $12,181,971.00 | $1,233,511.00 |
| Revenue This Year | N/A | $60.84 |
| Revenue Next Year | N/A | $404.89 |
| P/E Ratio | $32.15 | ★ N/A |
| Revenue Growth | 11.91 | ★ 59.10 |
| 52 Week Low | $5.58 | $0.17 |
| 52 Week High | $10.29 | $0.94 |
| Indicator | UG | VNRX |
|---|---|---|
| Relative Strength Index (RSI) | 44.85 | 38.64 |
| Support Level | $6.32 | $0.17 |
| Resistance Level | $6.74 | $0.33 |
| Average True Range (ATR) | 0.19 | 0.02 |
| MACD | -0.03 | 0.00 |
| Stochastic Oscillator | 40.38 | 33.37 |
United-Guardian Inc manufactures and markets cosmetic ingredients, pharmaceuticals, medical lubricants, and specialty industrial products. Its product portfolio includes Klensoft, Deselex, Renacidin, Lubrajel Fluid. The company's pharmaceutical products are sold to and distributed by full-line drug wholesalers throughout the United States. Its medical and specialty industrial products are sold directly by the company to the end-users of those products or, in some cases, to contract manufacturers used by some of those end users. It operates in one business segment and its current product lines are separated into four distinct product categories that are cosmetic ingredients, pharmaceuticals, medical lubricants and sexual wellness. It derives key revenue from the sales made in the U.S.
VolitionRX Ltd is a United States-based epigenetics company that applies its Nucleosomics platform through its subsidiaries to develop simple, easy-to-use, cost-effective blood tests to help diagnose and monitor range of life-altering diseases including some cancers and diseases associated with NETosis such as sepsis and COVID-19. The tests are based on the science of Nucleosomics, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present. The company is focused on human diagnostics and monitoring but also has a subsidiary focused on animal diagnostics and monitoring.